Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin

Young Suk Lee¹, Eduardo Davila², Tianshu Zhang¹, Hugh P Milmoe¹, Stefanie N Vogel², Jonathan S Bromberg¹,2 and Joseph R Scalea¹,2

Abstract

Myeloid-derived suppressor cells (MDSCs) inhibit T cell responses and are relevant to cancer, autoimmunity and transplant biology. Anti-thymocyte globulin (ATG) is a commonly used T cell depletion agent, yet the effect of ATG on MDSCs has not been investigated. MDSCs were generated in Lewis Lung Carcinoma 1 tumor-bearing mice. MDSC development and function were assessed in vivo and in vitro with and without ATG administration. T cell suppression assays, RT-PCR, flow cytometry and arginase activity assays were used to assess MDSC phenotype and function. MDSCs increased dramatically in tumor-bearing mice and the majority of splenic MDSCs were of the polymorphonuclear subset. MDSCs potently suppressed T cell proliferation. ATG-treated mice developed 50% fewer MDSCs and these MDSCs were significantly less suppressive of T cell proliferation. In vitro, ATG directly bound 99.6% of MDSCs. CCR7, L-selectin and LFA-1 were expressed by both T cells and MDSCs, and binding of LFA-1 was inhibited by ATG pre-treatment. Arg-1 and PD-L1 transcript expression were reduced 30–40% and arginase activity decreased in ATG-pretreated MDSCs. MDSCs were bound and functionally inhibited by ATG. T cells and MDSCs expressed common Ags which were also targets of ATG. ATG may be helpful in tumor models seeking to suppress MDSCs. Alternatively, ATG may inadvertently inhibit important T cell regulatory events in autoimmunity and transplantation.

Keywords

Transplant immunology, myeloid derived suppressor cells, Antithymocyte globulin, Tregs, transplantation tolerance

Introduction

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of naturally occurring immunosuppressive cells.¹ Common myeloid precursors develop into immature myeloid cells (IMCs).² Under non-inflammatory conditions, IMCs develop into dendritic cells, macrophages and neutrophils. In inflammatory environments, molecules such as G-CSF, IL-2, TGF-β, CXCL1/2 and S100A8/A9 redirect IMCs to develop into immunosuppressive MDSCs.³,4 MDSCs suppress T cell responses through nutrient depletion (via arginase-1), production of NO and reactive oxygen species, and through the expansion of T-regulatory cells.⁵,6

In mice, MDSCs are defined by the expression of the cell surface markers Gr-1 and CD11b. Total MDSCs are further categorized into two main subsets: monocytic MDSC (M-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs). M-MDSCs and PMN-MDSCs are differentiated phenotypically by the expression of Ly6C (M-MDSCs, CD11b⁺Ly6ChighLy6G⁻/CD0) and Ly6G (PMN-MDSC, CD11b⁺Ly6ClowLy6G⁺). In human cancers, and likely in transplantation, M-MDSCs and PMN-MDSCs have

¹Department of Surgery, University of Maryland, Baltimore, USA
²Department of Microbiology and Immunology, University of Maryland, Baltimore, USA

Corresponding author:
Joseph R Scalea, 29 S. Greene Street, Baltimore, MD 21201, USA.
Email: jscale002@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
different immunosuppressive potentials. In tumors, MDSC subset is also associated with location within the tumor microenvironment.

Because MDSCs suppress immune responses, they have garnered the attention of cancer, autoimmunity and transplant investigators. MDSCs are also important in pregnancy, as they contribute to fetal tolerance at the maternal–fetal interface. Cancer patients with higher MDSC responses have lower overall survival and cancer progression-free survival. MDSC function is aberrant in autoimmune processes such as inflammatory bowel disease. With regard to transplantation, MDSCs develop in humans after kidney transplantation, they suppress alloreactive T cell responses, and adoptively transferred MDSCs prolong renal allograft survival. MDSCs also home to transplanted organs and have been suggested as a pathway towards immunologic tolerance. There are only a few incomplete studies suggesting that immunosuppressive drugs affect MDSCs, yet the associated mechanisms are undefined. We hypothesized that because ATG is a polyclonal Ab which binds multiple cell types that ATG may also bind to and/or affect MDSCs. If MDSCs are affected by ATG, these findings would have implications for cancer, autoimmunity and transplant care.

The mechanism of action underlying the immunosuppressive activity of ATG has been studied extensively. ATG depletes T cells in peripheral blood and lymphoid tissues through complement dependent cytotoxicity. ATG also induces apoptosis, deregulates proliferation of B cells and impairs leukocyte/endothelium interactions through modulation of adhesion and cell-trafficking receptors. Despite its wide range of effects, the impact of ATG on MDSCs is poorly understood.

Here we sought to determine if ATG binds MDSCs. We then sought to determine how MDSC-ATG binding would affect MDSC function. We found that ATG readily bound MDSCs and that ATG impaired MDSC function.

Materials and methods

Animals

C57BL/6J and BALB/cJ mice (female, 6–8 wk old) were purchased from The Jackson Laboratories (Bar Harbor, ME). All mice were maintained in a specific pathogen-free animal facility. The Institutional Animal Care and Use Committees (IACUC) of the University of Maryland Baltimore approved all animal study protocols, and experiments were conducted in compliance with the Guide for the Care and Use of Laboratory Animals.

Reagents and tumor models

Lewis lung carcinoma (LLC1) cells are highly tumorigenic and stimulate MDSC expansion. LLC1 cells were cultured in RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 10% FBS (Gibco, Grand Island, NY), 100 U/ml penicillin and 100 µg/ml streptomycin (Gemini, Sacramento, CA) at 37°C in 5% CO2. For tumor challenge, LLC1 cells were injected subcutaneously into the right flank. Tumor growth was monitored twice a week and all tumors were 1–2 cm diameter within 2–3 wk. Tumor-bearing mice were euthanized 3 wk after LLC1 inoculation and MDSCs harvested. Mice were sacrificed if tumors exceeded 2 cm or became ulcerated. ATG was rabbit-anti-mouse and obtained from Earl Poptic in the Lerner Research Institute (Cleveland Clinic Hospital, Cleveland, OH), and injected intraperitoneally at 2 mg/kg for 5 d, as is similar in design to prior studies. PBS and rabbit serum were used as a control.

Abs and flow cytometry

Mouse spleens and lymph nodes were procured and tissues mashed through 70 µm strainers to generate single cells, which were suspended in PBS. Red blood cells were removed using an ACK lysis buffer (Lonza, Walkersville, MD). Samples were washed in magnetic activated cell sorting (MACS) buffer (1× PBS supplemented with 1% FBS and 2mmol/l EDTA), incubated with Fe receptor block (CD16/32, clone 2.4G; BD Bioscience, San Diego, CA) and stained for 30 min at 4°C with the relevant Abs. The following Abs were used for flow cytometry: Ly6C, Ly6G, CD11b, CD3ε, CD4, CD4, Gr-1, CD8, B220, CD25 FoxP3, CCR7, L-selectin, LFA-1 and PD-L1 (Supplemental Table 1). Functional grade purified anti-CD3ε (clone 145-2C11) and anti-CD28 (clone 37.51) for T cell activation were obtained from BD Pharmingen. Live/dead fixable aqua-dead stain or DAPI (Invitrogen) were used to assess viability prior to acquisition on flow cytometer. Samples were analyzed using the LSRFortessa flow cytometer (BD Biosciences, San Jose, CA) and FlowJo software (Tree Star, Ashland, OR).

Isolation of CD4+ T cells and MDSCs

CD4+ T cells were isolated from the spleen and lymph nodes of BALB/c mice using the EasySep™ Mouse CD4+ T Cell Isolation Kit (Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer’s instructions (Stem Cell Technologies, Vancouver, BC, Canada). Purity ranged between 90 and 99%, as determined by flow cytometry. MDSCs were isolated from spleens of tumor-bearing mice.
After 20 min of blocking the splenocytes with Fc block-
er, cells were stained with PE-conjugated Gr-1 Ab at
room temperature (25°C). PE-conjugated Gr-1+ MDSCs were selected by using magnetic nanoparticle
designed to bind with PE fluorochrome including in
The EasySep™ Mouse PE Positive Selection Kit
(Catalog #18554, Stem cells) and applying an
EasySep™ magnet. Gr-1 negative cells suspended in
the tube were poured off and Gr-1+ MDSCs bound
onto the tube were collected. Total MDSC
(Gr-1+CD11b+), PMN-MDSC (CD11b+Ly6G+ Ly6Clo)
and M-MDSC (CD11b+Ly6G+Ly6Chigh) were isolated by cell sorting using an ARIA II (Becton
Dickinson, San Diego, CA, USA; Supplemental Figure
1). Purity ranged from 98 to 99%.

**T Cell suppression assays**

CD4+ T cells were labeled with 5 μM carboxyfluoresce-
in succinimidyl ester (CFSE, Molecular Probes,
Eugene, Oregon) in 1 ml of PBS for 15 min at 37°C.
The labeling was halted by adding excess of FBS and
the samples were washed twice with RPMI 1640 sup-
plemented with 10% FBS. A total of 1 x 10^5 CFSE-
labeled CD4+T cells were plated in complete media
(RPMI 1640, 10% FBS, 20 units/ml penicillin, 50 mg/
ml streptomycin) supplemented with 2 mmol/l l-gluta-
mine and 0.05 mmol/l 2-mercaptoethanol onto flat-
bottomed 96-well plates (Corning, B.V.) coated with
5 μg/ml anti-CD3 and 2 μg/ml anti-CD28 (eBioscience). MDSCs were added in T cell:MDSC
ratios of 1:0.5, 1:1 and 1:2. Cells were cultured for 3 d.
MDSCs were pre-incubated with 10 μg mitomycin C
for 1 h prior to co-culture with T cells.

**In-vitro ATG binding assay**

For blocking non-specific binding of ATG to Fc recep-
tors, MDSCs were pre-incubated with purified anti-
mouse CD16/32 Ab for 20 min. Then, MDSCs
(1 x 10^5 cells) were incubated for 30 min with serial
dilutions of ATG (0.25 μg–100 μg) at 4°C. Purified
normal rabbit serum (‘normal serum’ or ‘NS’) was
used as a control. Following two washes with 1× PBS,
a FITC-conjugated goat-anti-rabbit IgG secondary
Ab was added to the cells and further incubated for
30 min at 4°C. The cells were fixed with 4% PFA for
10 min at 4°C. After washing, cells were harvested and
FITC signal of gated MDSCs was measured by
flow cytometry.

**Arginase activity assay**

The enzymatic activity of arginase was determined by
measuring the conversion of l-arginine to l-ornithine
and urea using the Arginase Activity Assay Kit
(Sigma Aldrich, St. Louis, MO) in Gr-1+ MDSCs
and Gr-1- (Non-MDSC) cells. The procedures were
performed according to the manufacturers’ protocols.
Briefly, cells were treated with 5 μg/ml or 50 μg/ml of
ATG, rabbit normal serum (NS), or PBS and incuba-
ed for 24 h in 5% CO2 incubator at 37°C. Each group
of cells was washed twice with 1× PBS and lysed with
200 μl of lysis buffer-containing 0.4% Triton X-100, 10
mM Tris-HCl (pH 7.5) and 1 μM Pepstatin and
Leupeptin protease inhibitor. After centrifugation at
13,000 g for 10 min, the supernatant was collected
and placed into 96-well plates. Arginase was activated
by adding l-arginine substrate buffer and incubation
for 2 h at room temperature. l-arginine hydrolysis was
done by incubating the activated lysates with 50 μl of
l-arginine (pH 9.7) at 37°C for 60 min. The reaction
was stopped by the addition of 200 μl urea stop buffer
and urea concentration was measured at 540 nm after
using a spectrophotometer (Thermo Fisher Scientific,
Waltham, MA) followed by incubation at room tem-
perature for 60 min. One unit of arginase is the
amount of enzyme that will convert 1.0 μmole of l-
arginine to ornithine and urea per minute at pH 9.5
and 37°C.

**RNA isolation and real-time quantitative RT-PCR**

Total RNA isolation was performed using the RNasey RNA isolation kit according to the manufac-
turer's instructions (Qiagen, Waltham, MA). The
quality and integrity of RNA were evaluated via
A260/A280 ratio by using Nanodrop 2000 Spectrometer (ThermoFisher Scientific). Thereafter,
1–3 μg of total RNA were reverse transcribed to
first-strand cDNA using the RevertAid First Strand
cDNA Synthesis Kit (Thermo Fisher Scientific). qRT-
PCR was performed in duplicate using All-in-One
qPCR Mix (GeneCopoeia, Inc., Rockville, MD). An
Eppendorf Mastercycler Realplex PCR system was
used as follows: initial denaturation 95°C for 10 min,
followed by 40 cycles of denaturation at 95°C for 10 s,
annealing at 60°C for 20 s and extension at 72°C for
15 s. GAPDH was used as an internal control for
normalization.

**Statistical analysis**

Where appropriate (MDSC number, spleen mass, con-
tinuous numeric values, etc.), data are presented as
mean value ± standard error (SEM). The independent
Student’s t-test was used to compare the difference of
mean between each of two groups. Data were analyzed
using Graph Pad Prism V6.0 (LaJolla, CA,).
Results

MDSCs are expanded in tumor-bearing mice

Animals injected with LLC1 cells uniformly developed tumors. Based on prior data suggesting that MDSCs develop in large numbers by 3 wk,36 animals were euthanized, and tissues were obtained at this time. Spleens of tumor-bearing mice were significantly larger than those of naïve animals (Figure 1a). Spleen mass and splenocyte number were 4-fold higher (4.09 ± 0.65; \( P < 0.001 \); Figure 1b) and 10-fold higher (10.57 ± 4.4; \( P < 0.05 \); Figure 1c), respectively, compared with controls. Total Gr-1\(^+\)CD11b\(^+\) MDSCs were compared between animals with and without tumor. Gr-1\(^+\)CD11b\(^+\) MDSCs increased (>7-fold) to comprise more than 15% of total splenocytes in tumor-bearing mice v. less than 4% for naïve mice (Figure 1d). MDSC subsets (PMN-MDSCs and M-MDSCs) from the spleens of naïve and tumor-bearing mice were also assessed (Figure 1e and f).

Figure 1. MDSCs are significantly expanded in spleen of tumor-bearing C57Bl/6 mice. One million (1 \( \times \) 10\(^6\) cells) of Lewis lung carcinoma LLC1 cells were inoculated in the flank of C57Bl/6 female mice. Three wk after tumor inoculation, all the mice were burdened with tumor. (a–c) Spleens from naïve or tumor-bearing mice were harvested and mass and total number of splenocyte were measured. Splenocytes were subjected to immunophenotyping by flow cytometry. (d, i and ii). Representative gating strategy for identification of total MDSCs, M-MDSC and PMN-MDSC. (f) The frequency of total MDSCs (GR-1\(^+\)CD11b\(^+\)) (d) and M-MDSCs (CD11b\(^+\)Ly6G\(^-\)Ly6Chigh)PMN-MDSCs (CD11b\(^+\)Ly6G\(^-\)Ly6C\(^{low}\)) M- and PMN-MDSCs were subsequently identified based on the expression of CD11b, Ly6C and Ly6G, respectively (\( n = 5 \)). **: \( P < 0.05 \) for statistically significant differences between naïve and tumor-bearing mice.

In naïve mice PMN-MDSCs (CD11b\(^+\)Ly6G\(^+\)Ly6C\(^{low}\)) and M-MDSCs (CD11b\(^+\)Ly6G\(^-\)Ly6C\(^{high}\)) comprised 1.7 and 0.7% of splenocytes, respectively, and the ratio of PMN-MDSC:M-MDSC was 2:1. In tumor-bearing mice PMN-MDSCs and M-MDSCs comprised 20.6 and 2.8% of splenocytes, respectively, and the ratio between these two populations was increased to 8:1. Our results thus indicate that LLC1 tumors induced the expansion of Gr-1\(^+\)CD11b\(^+\) MDSCs, and of these MDSCs the majority were of the PMN-MDSC subtype.

MDSCs suppress T cell proliferation in vitro

T cell suppression is a defining feature of MDSCs.37 CD4\(^+\) T cells isolated from peripheral lymph nodes and spleen of BALB/c and were stimulated with anti-mouse CD3/CD28 and co-cultured with or without MDSCs from tumor-bearing BALB/c or C57Bl/6J. MDSCs, in a dose-dependent fashion, potently suppressed Ab-induced T cell proliferation (Figure 2).
We next assessed the effect of ATG on MDSCs, T cell subsets and B cells in treated and untreated tumor-bearing animals. Splenocytes from tumor-bearing animals were stained with variety of cell surface markers including anti-CD11b, anti-Gr-1, anti-CD4, anti-CD8, anti-CD25 and anti-B220 to assess phenotype with and without ATG treatment (Figure 3a). Tumor size and spleen size were not affected by ATG treatment (data not shown). The total splenic cell number was also unaffected by ATG treatment when compared with PBS-treated controls (Figure 3b). ATG led to a >50% decrease in Gr-1⁺CD11b⁺ MDSCs among splenocytes (Figure 3c; P < 0.05, n = 6), and this was associated with a concomitant decrease in MDSC absolute number (Supplemental Figure 2). Consistent with the known effects of ATG, T cell populations were also decreased by ATG treatment when compared with PBS-treated controls (Figure 3b–f). We did not detect a statistically significant reduction in B cell numbers in ATG treated mice (n = 6; Figure 3c–f). We did not detect a statistically significant reduction in B cell numbers in ATG treated mice (n = 6; Figure 3c–f). We did not detect a statistically significant reduction in B cell numbers in ATG treated mice (n = 6; Figure 3c–f). We did not detect a statistically significant reduction in B cell numbers in ATG treated mice (n = 6; Figure 3c–f). We did not detect a statistically significant reduction in B cell numbers in ATG treated mice (n = 6; Figure 3c–f).

**ATG directly binds and inhibits MDSC in vitro**

We next assessed whether the observed effects of ATG on MDSCs were the result of direct ATG–MDSC binding. MDSCs from tumor-bearing mice were isolated and incubated with serial dilutions of ATG (0.25–100 μg/ml) or normal rabbit serum. Cells were then washed and stained with FITC-conjugated anti-rabbit IgG (Figure 5a). ATG bound to MDSCs in a dose-dependent fashion (Figure 5b). Weak binding was observed at an ATG dose of 1 μg/ml, however, binding increased to 8% at a dose of 2 μg/ml. More than 59% of MDSCs were bound at 4 μg/ml of ATG. Saturation (>99%) occurred at 8 μg/ml (Figure 5b and c). To assess and avoid non-specific binding of ATG to Fc receptors (FcR) on MDSCs, FcR blocker was used to pretreat MDSCs in advance of incubation with ATG. FcR blockade did not affect capacity of ATG to bind MDSCs, indicating that ATG binding was specific. We then investigated if ATG binding would affect MDSC function in vitro. Indeed, we found that ATG treated MDSCs were less suppressive of T cell proliferation (Figure 6a and b, P < 0.001). At a T cell:MDSC ratio of 1:2, ATG-treated MDSCs were 3× less suppressive of T cell responses when compared with normal rabbit-serum-treated MDSCs (Figure 6c). Consistent with previous data, PMN-MDSCs and M-MDSCs were both suppressive of T cell proliferation, and both subsets were inhibited by ATG. Notably, PMN-MDSCs appeared to be suppressed by ATG to a greater degree than were M-MDSCs (Figure 6d, P < 0.0001).
Together, these data suggest that ATG treatment, *in vitro*, inhibited MDSC function.

**MDSCs and T cells express common Ags that are bound by ATG**

As ATG is polyclonal, it is possible that MDSC depletion resulted from ATG binding of T cell Ags also expressed on MDSCs. To determine if T cells and MDSCs expressed common Ags which might act as ATG targets, we sought to determine if T cells and MDSCs expressed common Ags which, based on the literature, were also known targets of ATG (CCR7, L-selectin and LFA-1). In our hands, we observed that both T cells and MDSCs expressed CCR7, L-selectin and LFA-1 (Figure 7a). We next sought to determine if ATG pretreatment would block binding of our selected Abs, suggesting (albeit indirectly) that our selected Ags were also ATG targets. T cells and MDSCs were pretreated with ATG. Thereafter, we again stained for CCR7, L-selectin and LFA-1, using their respective Abs. ATG pre-treatment led to decreased LFA-1 binding, suggesting that LFA-1 was bound by ATG (Figure 7b).

**ATG suppresses Arg1 and PD-L1 transcript expression and arginase-1 activity**

MDSC-mediated T cell suppression in cancers and in transplantation occurs, among other mechanisms, through the actions of arginase-1, iNOS and PD-L1. The expression of each of these molecules was
measured with and without ATG treatment. Real-time PCR analysis showed that, after ATG treatment, transcriptional expression of Arg-1 was decreased approximately 30% and PD-L1 approximately 40%. Expression of iNOS was unchanged (Figure 7c). Because Arg-1 expression by PCR was decreased after ATG treatment, we next sought to determine if there was a coincident decrease in arginase activity with ATG treatment. Arginase activity was measured in ATG-treated and control MDSCs by lysing MDSCs and collecting the supernatant. As anticipated, we observed that MDSCs had greater arginase activity than did non-MDSC splenocytes, consistent with their suppressive phenotype. ATG treatment was associated with a dose-dependent decrease in MDSC arginase production (Figure 7d). These data suggest that, outside of ATG mediated depletion, ATG also affects MDSC function.

Discussion

ATG is a commonly used polyclonal T-cell depleting antibody. Little is known about the effects of ATG on MDSCs. In testing how ATG might affect MDSCs, we observed that ATG binds to MDSCs directly. ATG binding to MDSC led to MDSC depletion and suppression of MDSC function. ATG, at least partly, affected MDSCs’ ability to produce arginase. These effects on MDSCs may have important implications for cancer, autoimmunity and transplant biology. Few MDSCs were produced in naïve mice and tumor inoculation dramatically induced MDSC expansion. Different inflammatory milieus (i.e. type of cancer, trauma, etc.) yield different numbers and ratios of PMN-MDSCs and M-MDSCs v. total MDSCs. For example, when cancer types were compared, sarcoma-bearing mice generated the fewest number of MDSCs, whereas colon cancers led to much higher levels. Differences in MDSC expansion are likely due to differences in the inflammatory stimuli which exist between tumor types. M-MDSCs are potently immunosuppressive and are found in greater number within, rather than external to, tumors. PMN-MDSCs are thought to be less immunosuppressive than M-MDSCs, and can be identified peripherally. In our hands, a 15-fold increase in MDSC expansion in tumor-bearing mice was observed. The vast majority of the MDSCs present among splenocytes were PMN-MDSCs and the ratio of PMN:M-MDSC increased 4-fold in tumor-bearing mice, consistent with the literature which suggests that approximately 70% of MDSCs outside the tumor are PMN-MDSCs. Furthermore, in vitro, the suppressive activity of PMN-MDSCs appeared to be disproportionately affected by ATG treatment when compared with M-MDSCs. In patients with cancer, MDSCs are directed against the host’s own T cells. Thus, there is no MHC disparity between the T cell and the MDSC. However, in transplantation, MDSCs or T cells may be from donor (e.g. transplanted leukocytes, or ‘passenger
leukocytes') or from the recipient. Further, MDSCs develop in human kidney transplant recipients after transplantation. We found that MDSCs efficiently suppressed autologous and MHC disparate T cell proliferation. These data are important for the present study, because they suggest that ATG may detrimentally suppress potentially helpful MDSC-mediated T cell regulation after transplantation.

ATG is a polyclonal Ab purified from rabbits immunized with donor T cells. Thus, cells that express Ags common to T cells may also be bound by ATG. ATG is known to bind multiple immune cell subsets including B cells, natural killer cells, monocytes and dendritic cells. We hypothesized that MDSCs may also be bound by ATG. Indeed, our ATG binding assay showed that MDSCs were bound by ATG in a dose-dependent manner. We reasoned that ATG–MDSC binding likely resulted from the expression by MDSCs of Ags also expressed by T cells. To test this hypothesis, we reviewed the literature and identified CCR7, L-selectin and LFA-1 as targets of ATG on T cells. In our hands, we observed that each Ag was expressed on both T cells and MDSCs. To determine which of these shared Ags were also bound by ATG, we pretreated T cells and MDSCs with ATG and observed a decrease in LFA-1 binding. CCR7 and L-selectin were not affected by ATG pre-treatment. This is interesting, because all three of the antigens are known targets of ATG on T cells. It is possible that in contrast to LFA-1, ATG bound to antigenic epitopes on CCR7 and L-selectin that were distinct from the antigenic targets of the Abs used to detect these molecules. These epitope differences may explain why ATG pre-treatment did not affect subsequent CCR7 and L-selectin binding. It is very likely that many other antigens are expressed by both T cells and MDSCs. A review of the literature suggests that CCR2, CD66b, TGF-β, IFN-γR and IL-4R may also be expressed by both cell types and therefore recognized by ATG.

Many studies have shown that ATG induces cell death by complement-dependent cytotoxicity.

![Figure 5](https://example.com/figure5.png)

**Figure 5.** ATG bind physically with MDSCs in vitro. A million number of Gr-1⁺ MDSCs were incubated with a serial dilution of ATG (0.25–100 µg/ml) for 30 min at 4°C. Normal serum and PBS (data not shown) were used as controls. Following washing twice, FITC-conjugated goat-anti-rabbit IgG was added and further incubated for 30 min. (a) The typical example of flow cytometry and (b) representative histogram data. (c) Densitometric data indicating the percentile of cells bound by ATG.
Figure 6. ATG inhibits the suppressive function of MDSCs. Following incubation with ATG (2 μg/ml) for 30 min, MDSCs were collected and were assessed for their suppressive activity by co-culturing with CD4 T cells as described in Figure 2. (a) Representative plot of a sample of T cell proliferation monitored 72 h later by flow cytometry. (b) Densitometric data and (c) statistically significant differences between serum and ATG-treated MDSCs. (d) PMN-MDSCs and M-MDSCs subsets incubated with ATG or control serum and co-cultured with CD4 T cells for 72 h. Cell proliferation was measured in triplicates and mean ± SD is shown. *, P < 0.05, **, P < 0.01, ***, P < 0.001.
Figure 7. Expression of common Ags CCR7, L-selectin and LFA-1 on T cells and MDSCs, and ATG's effect on expression of Arg-1 and PD-L1 and arginase levels. Splenocytes were collected and analyzed for the expression of LFA-1, L-selectin, CCR7 and PD-L1 by flow cytometry in T cells and MDSCs. (a) Representative histogram showed the expression of tested markers in CD4+ T cell and CD8+ T cells and Gr-1+CD11b+ MDSCs. Normal line indicates isotype control and dotted line indicate designated protein expression. (b) To determine if ATG bind and affect one of these common Ag, cells were incubated with 5 μg of ATG for 1h at 4°C prior to staining with primary Abs. Besides ATG treatment, same flowcytometry procedures were applied. Each representative histogram showed the difference in the expression of markers in the cells with or without ATG. Line indicate rabbit serum treated cells and shaded indicated ATG-treated cells. (c) Following incubation with ATG (2 μg/ml) for 30 min, MDSCs were collected and assessed for transcriptional expression of Arg-1 and iNOS, and PD-L1. (d) Arginase activity was assessed both in Gr-1+ MDSCs or Gr-1− cells. Each group of cells were incubated 24 h in the presence of 5 or 50 μg/ml of ATG. Normal rabbit serum (serum) was used as a control. All the procedures were performed as described in ‘Materials and methods’ and the enzyme activity (unit/l) was calculated by the formula provided by protocol guideline. In real-time qRT-PCR assay, expression of the interested genes was normalized to the expression of GAPDH. *, P < 0.05, ***, P < 0.01, ns: not statistically significant.
Further, ATG’s complement dependent cytotoxicity is dose-dependent. Beyond T cells, Cumpelic et al. demonstrated ATG also binds and depletes platelets in a complement dependent manner. Ayuk et al. suggested that ATG also causes caspase-dependent cell death, but that this was complement-independent. To this end, we have reasoned that MDSC depletion by ATG treatment is, at least in part, complement dependent. Beyond MDSC depletion, T cell-MDSC interactions may have been indirectly affected by ATG. For example, IL-10 is known to maintain MDSCs in cancer models. MDSCs also generate NO through inducible NO synthase (iNOS). MDSCs can expand the T regulatory cell population, at least in part, through the expression of PD-L1. MDSCs derived from ATG-treated tumor-bearing mice down-regulated Arg-1 and PD-L1, perhaps explaining MDSC loss of function. The reduction in Arg-1 mRNA expression was associated with a decrease in arginase activity. However, arginase reduction was only partial (c. 15% absolute reduction), suggesting (perhaps) that even small decreases in arginase production translate to substantial losses of MDSC function. Perhaps more likely, the observed loss of MDSC function was multifactorial, resulting from a combination of MDSC depletion, steric hindrance of regulatory proteins via ATG, in addition to ATG-mediated suppression of Arg-1 and PD-L1.

Other immunosuppressive agents also affect MDSCs. Glucocorticoid antagonism suppresses the

---

**Figure 7. Continued**

![Graphs showing mRNA expression and Arginase activity](image-url)
MDSC response to inflammation.\textsuperscript{56} Cyclosporine may enhance the suppressive nature of MDSCs secondary to iNOS up-regulation, however the effect of tacrolimus, a calcineurin inhibitor, is poorly understood.\textsuperscript{23} mTOR inhibitors such as rapamycin have been shown to suppress MDSC function, though they are also known to paradoxically upregulate iNOS and Arg1.\textsuperscript{37,58} Monoclonal Abs such as Alemtuzumab, Basiliximab and Rituximab are poorly understood. Beyond induction agents, there are no focused studies of chronic immunosuppressive agents such as tacrolimus, belatacept, or mycophenolate mofetil and their effects on MDSCs in the transplant setting.\textsuperscript{23}

T cell depletion in blood and peripheral lymphoid tissues is the primary immunomodulatory effect of ATG, particularly in transplantation.\textsuperscript{27,59} However, accumulating evidence suggests that, beyond T cell depletion, ATG may also stimulate T regulatory cells (Treg).\textsuperscript{60–62} Indeed, Lopez et al. tested the ability of ATG to induce the generation of Tregs and found that ATG expanded CD4\(^+\)CD25\(^+\) T cells and up-regulated expression of CTLA-4 and Foxp3 in the expanded cells.\textsuperscript{63} In an \textit{in-vitro} model assessing the impact of ATG, Buszko et al. recently showed that Foxp3\(^+\) Tregs can be expanded with ATG treatment as well, however, ATG mediated Foxp3\(^+\) expansion was transient and ATG mediated effects appeared to decline 10 d after ATG treatment.\textsuperscript{64} These data suggest that ATG has immunomodulatory effects that go beyond T cell depletion. Thus, Foxp3\(^+\) Tregs generated as a result of ATG may have a protective role in delaying transplant rejection. Boenisch et al. suggested that ATG reprograms CD4\(^+\) T cells to become Tregs, and this transition was STAT3-dependent.\textsuperscript{65} Additional evidence suggests that ATG preferentially depletes conventional T (Tconv) cells, but that it spares Tregs. Taken together, ATG can affect Tregs as well as MDSCs.\textsuperscript{43} Because T cell proliferation in this study was enhanced by ATG administration, it is possible that ATG had a greater effect on MDSCs than on Tregs, however this important topic requires additional investigation.

MDSCs are potently immunosuppressive and are associated with metastases and poor survival in cancer patients.\textsuperscript{12,14} MDSCs suppress T cell responses at the maternal–fetal interface\textsuperscript{66} and they display aberrant function in autoimmune settings.\textsuperscript{15} Further, MDSCs develop after organ transplants and may prolong graft survival.\textsuperscript{7} In this regard, it may be worth studying in detail the effects of ATG in models of transplantation, specifically examining its effects on MDSCs and how these might alter transplant outcomes. Beyond transplantation, ATG may have also a role in targeting MDSCs in cancer treatment. Since the mechanisms underlying ATG-induced functional modulation are understudied, further investigations of its effects on MDSC biology are needed to better understand its role in cancer, embryology, autoimmunity and in transplantation.

\textbf{Acknowledgment}

We are grateful to the American Surgical Association for a junior faculty development award.

\textbf{Declaration of conflicting interests}

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

\textbf{Funding}

The author(s) received no financial support for the research, authorship, and/or publication of this article.

\textbf{References}

1. Kumar V, Patel S, Tcyganov E, et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment. \textit{Trends Immunol} 2016; 37(3): 208–220.
2. Scalea JR, Lee, Y. S., Davila, E., et al. Myeloid-derived suppressor cells and their potential application in transplantation. \textit{Transplantation} 2018; 102(3): 359–367.
3. He Z, Riva M, Bjork P, et al. CD14 is a co-receptor for TLR4 in the S100A9-induced pro-inflammatory response in monocytes. \textit{PLoS One} 2016; 11(5): e0156377.
4. Greifenberg V, Ribecheini E, Rossner S, et al. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. \textit{Eur J Immunol} 2009; 39(10): 2865–2876.
5. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. \textit{Cancer Res} 2009; 69(4): 1553–1560.
6. Haverkamp JM, Crist SA, Elzey BD, et al. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. \textit{Eur J Immunol} 2011; 41(3): 749–759.
7. Luan Y, Mosheir E, Menon MC, et al. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4\(^+\) Foxp3\(^+\) Treg expansion. \textit{Am J Transplant} 2013; 13(12): 3123–3131.
8. Marvel D and Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. \textit{J Clin Invest} 2015; 125(9): 3356–3364.
9. Ochando JC and Chen SH. Myeloid-derived suppressor cells in transplantation and cancer. \textit{Immunol Res} 2012; 54(1–3): 275–285.
10. Zhao AM, Xu HJ, Kang XM, et al. New insights into myeloid-derived suppressor cells and their roles in fetomaternal immune cross-talk. \textit{J Reprod Immunol} 2016; 113: 35–41.
11. Kostlin N, Hofstadter K, Ostermeir AL, et al. Granulocytic myeloid-derived suppressor cells accumulate in human placenta and polarize toward a Th2 phenotype. \textit{J Immunol} 2016; 196(3): 1132–1145.
12. Zhang S, Ma X, Zhu C, et al. The role of myeloid-derived suppressor cells in patients with solid tumors: A meta-analysis. *PLoS One*. 2016; 11(10): e0164514.

13. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. *Cancer Immunol Immunother* 2009; 58(1): 49–59.

14. Sun HL, Zhou X, Xue YF, et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. *World J Gastroenterol* 2012; 18(25): 3303–3309.

15. Kontaki E, Boumpas DT, Tzardi M, et al. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. *Autoimmunity* 2017; 50(3): 170–181.

16. He Y, Wang B, Jia B, et al. Effects of adoptive transferring different sources of myeloid-derived suppressor cells in mice corneal transplant survival. *Transplantation* 2015; 99(10): 2102–2108.

17. Ramachandran IR, Condamine T, Lin C, et al. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. *Cancer Lett* 2016; 371(1): 117–124.

18. Drujont L, Carretero-Iglesia L, Bouchet-Delbos L, et al. Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection. *PLoS One*. 2014; 9(6): e100013.

19. Dugast AS, Haudebourg T, Coulon F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. *J Immunol* 2008; 180(12): 7898–7906.

20. Guillonneau C. Efficacy of myeloid derived suppressor cells on transplant survival. *Transplantation* 2015; 99(10): 2017–2019.

21. Garcia MR, Ledgerwood L, Yang Y, et al. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. *J Clin Invest* 2010; 120(7): 2486–2496.

22. Zhang C, Wang S, Yang C, et al. The crosstalk between myeloid derived suppressor cells and immune cells: To establish immune tolerance in transplantation. *J Immunol Res* 2016; 2016: 4986797.

23. Han C, Wu T, Na N, et al. The effect of immunosuppressive drug cyclosporine A on myeloid-derived suppressor cells in transplanted mice. *Inflamm Res* 2016; 65(9): 679–688.

24. Zhang K, Bai X, Li R, et al. Endogenous glucocorticoids promote the expansion of myeloid-derived suppressor cells in a murine model of trauma. *Int J Mol Med* 2012; 30(2): 277–282.

25. Iwasaki Y, Porter KA, Amend JR, et al. The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. *Surg Gynecol Obstet* 1967; 124(1): 1–24.

26. Starzl TE, Marchioro TL, Porter KA, et al. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. *Surg Gynecol Obstet* 1967; 124(2): 301–308.

27. Ayuk FA, Fang L, Fehse B, et al. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. *Exp Hematol* 2005; 33(12): 1531–1536.

28. Wolf D, Jehle F, Ortiz Rodriguez A, et al. CD40L deficiency attenuates diet-induced adipose tissue inflammation by impairing immune cell accumulation and production of pathogenic IgG-Abs. *PLoS One* 2012; 7(3): e33026.

29. Zand MS, Yo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. *Transplantation* 2005; 79(11): 1507–1515.

30. Bonnefoy-Berard N, Flacher M and Revillard JP. Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. *Blood* 1992; 79(8): 2164–2170.

31. Bonnefoy-Berard N, Vincent C, Verrier B, et al. Monocyte-independent T-cell activation by polyclonal antithymocyte globulins. *Cell Immunol* 1992; 143(2): 272–283.

32. Walther S, Beiras-Fernandez A, Csapo C, et al. Influence of polyclonal antithymocyte globulins on the expression of adhesion molecules of isolated human umbilical vein endothelial cells. *Transplant Proc* 2010; 42(5): 1931–1934.

33. Savai R, Langheinrich AC, Schermuly RT, et al. Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. *Neoplasia* 2009; 11(1): 48–56.

34. Hoepppner LH, Wang Y, Sharma A, et al. Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. *Mol Oncol* 2015; 9(1): 270–281.

35. Hongo D, Tang X, Baker J, et al. Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. *Am J Transplant* 2014; 14(11): 2467–2477.

36. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. *J Immunol* 2008; 181(8): 5791–5802.

37. Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun* 2016; 7: 12150.

38. Gianello PR, Fishbein JM, Rosengard BR, et al. Tolerance to class I-disparate renal allografts. *Transplantation* 2002; 73(9): 1501–1507.

39. Kreisel D, Petrowsky H, Krasinskas AM, et al. The role of passenger leukocyte genotype in rejection and acceptance of rat liver allografts. *Transplantation* 2002; 73(9): 1501–1507.

40. Rebellato LM, Gross U, Verbanac KM, et al. A comprehensive definition of the major Ab specificities in polyclonal rabbit antithymocyte globulin. *Transplantation* 1994; 57(5): 685–694.

41. Gillet-Hladky S, de Carvalho CM, Bernaud J, et al. Rabbit antithymocyte globulin inhibits...
monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase. Transplantation 2006; 82(7): 965–974.

42. Roeder T, Katzfluss M, Matos C, et al. Antithymocyte globulin induces a tolerogenic phenotype in human dendritic cells. Int J Mol Sci 2016; 17(12): 2081.

43. Xia CQ, Chernaytsynska AV, Wasserfall CH, et al. Antithymocyte globulin (ATG) differentially depletes naive and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice. BMC Immunology 2012; 13: 70.

44. Sinha P, Parker KH, Horn L, et al. Tumor-induced myeloid-derived suppressor cell function is independent of IFN-gamma and IL-4Ralpha. Eur J Immunol 2012; 42(8): 2052–2059.

45. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21(7): 1387–1394.

46. Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91(7): 2360–2368.

47. Beider K, Naor D, Voevoda V, et al. Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation: Potential implications for graft versus host disease. Oncotarget 2017; 8(53): 90748–90765.

48. Cumpelik A, Gerossier E, Jin J, et al. Mechanism of platelet activation and hypercoagulability by antithymocyte globulins (ATG). Am J Transplant 2015; 15(10): 2588–2601.

49. Na IK, Wittenbecher F, Dziubianau M, et al. Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica 2013; 98(1): 23–30.

50. Ayuk FA, Atassi N, Schuch G, et al. Complement-dependent and complement-independent cytolysis of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. Leuk Res 2008; 32(8): 1200–1206.

51. Pintino L, Solito S, Damuzzo V, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget 2016; 7(2): 1168–1184.

52. Bronte V, Serafini P, De Santo C, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170(1): 270–278.

53. Ruber PL, Thévenot P, Sierra R, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer 2014; 134(12): 2853–2864.

54. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69(6): 2514–2522.

55. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66(2): 1123–1131.

56. Makarenkova VP, Bansal V, Matta BM, et al. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006; 176(4): 2085–2094.

57. Wu T, Zhao Y, Wang H, et al. mTOR masters monocyte myeloid-derived suppressor cells in mice with allografts or tumors. Sci Rep 2016; 6: 20250.

58. Zhang C, Wang S, Li J, et al. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury. Cell Death Dis 2017; 8(3): e2695.

59. Mohty M, Gaugler B. Mechanisms of action of antithymocyte globulin: old dogs with new tricks! Leuk Lymphoma 2008; 49(9): 1664–1667.

60. Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFoxp3+ regulatory T cells in vitro. Blood 2008; 111(7): 3675–3683.

61. Shimony O, Nagler A, Gellman YN, et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J Clin Immunol 2012; 32(1): 173–188.

62. Sewgobind VG, van der Laan LJ, Kho MM, et al. Characterization of rabbit antithymocyte globulins induced CD25+ regulatory T cells from cells of patients with end-stage renal disease. Transplantation 2010; 89(6): 655–666.

63. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006; 17(10): 2844–2853.

64. Buszko M, Jakic B, Ploner C, et al. In vitro immunoregulatory effects of thymoglobin on human immune cell subpopulations. Immunol Lett 2017; 186:1–8.

65. Boenisch O, Lopez M, Elyaman W, et al. Ex vivo expansion of human Tregs by rabbit ATG is dependent on intact STAT3-signaling in CD4(+) T cells and requires the presence of monocytes. American J Transplant 2012; 12(4): 856–866.

66. Raghupathy R. Maternal anti-placental cell-mediated reactivity and spontaneous abortions. Am J Reprod Immunol 1997; 37(6): 478–484.